C

    Celcuity LLC (CELC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $89.06
    +0.62 (+0.70%)

    Market Cap: $4.33B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(19/36)
    Avg Surprise
    -8.01%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.51
    Range$-1.60 - $-1.42
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-1.08+28.1%
    60d ago$-1.08+28.1%
    30d ago$-1.18+21.9%
    7d ago$-1.18+21.9%
    Current$-1.51
    Revenue Consensus
    $3M
    Range$0 - $10M
    10 analysts
    Dec 31, 2026
    EPS Consensus$-0.91
    Range$-1.00 - $-0.82
    2 analysts
    Revenue Consensus
    $34M
    Range$7M - $55M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.91---
    Sep 26EST
    		-$-1.51---
    Jun 26
    		$-1.44$-1.08-33.33%Miss-54.8%
    Mar 26
    		$-0.86$-0.89+3.37%Beat-6.2%
    Dec 25
    		$-0.73$-1.05+30.48%Beat+2.7%
    Sep 25
    		$-0.78$-0.96+18.75%Beat-20.0%
    Jun 25
    		$-0.93$-0.84-10.71%Miss-60.3%
    Mar 25
    		$-0.81$-0.86+5.81%Beat-26.6%
    Dec 24
    		$-0.75$-0.67-11.94%Miss-23.0%
    Sep 24
    		$-0.65$-0.70+7.14%Beat+16.7%
    Jun 24
    		$-0.58$-0.55-5.45%Miss+0.0%
    Mar 24
    		$-0.64$-0.71+9.86%Beat-36.2%
    Dec 23
    		$-0.61$-0.75+18.67%Beat+11.6%
    Sep 23
    		$-0.78$-0.53-47.17%Miss-4.0%
    Jun 23
    		$-0.58$-0.46-26.09%Miss-5.5%
    Mar 23
    		$-0.47$-0.43-9.30%Miss+11.3%
    Dec 22
    		$-0.69$-0.44-56.82%Miss-86.5%
    Sep 22
    		$-0.75$-0.60-25.00%Miss-114.3%
    Jun 22
    		$-0.55$-0.48-14.58%Miss+16.7%
    Mar 22
    		$-0.53$-0.51-3.92%Miss-152.4%
    Dec 21
    		$-0.37$-0.35-5.71%Miss-76.2%
    Sep 21
    		$-0.35$-0.24-45.83%Miss-45.8%
    Jun 21
    		$-0.66$-0.21-214.29%Miss-288.2%
    Mar 21
    		$-0.21$-0.20-5.00%Miss-23.5%
    Dec 20
    		$-0.21$-0.22+4.55%Beat-50.0%
    Sep 20
    		$-0.24$-0.23-4.35%Miss-50.0%
    Jun 20
    		$-0.17$-0.18+5.56%Beat-13.3%
    Mar 20
    		$-0.17$-0.17+0.00%Beat-6.3%
    Dec 19
    		$-0.14$-0.18+22.22%Beat+6.7%
    Sep 19
    		$-0.16$-0.17+5.88%Beat-6.7%
    Jun 19
    		$-0.15$-0.18+16.67%Beat+0.0%
    Mar 19
    		$-0.16$-0.20+20.00%Beat+0.0%
    Dec 18
    		$-0.15$-0.18+16.67%Beat-7.1%
    Sep 18
    		$-0.15$-0.18+16.67%Beat+25.0%
    Jun 18
    		$-0.15$-0.17+11.76%Beat-36.4%
    Mar 18
    		$-0.16$-0.19+15.79%Beat-
    Dec 17
    		$-0.14$-0.15+6.67%Beat-
    Sep 17
    		$-0.20$-0.19-5.26%Miss-
    Jun 17
    		$-0.11N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-23.38EV/EBITDA-7.80x
    Price/FCF-25.41xFCF Yield-3.94%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-1434.00%ROIC1090.23%
    Financial Health
    Debt/Equity-0.02xInterest Coverage-5.27x
    Current Ratio8.93xQuick Ratio8.93x
    Trading Statistics
    Beta0.20Avg Volume746.00K
    52-Week High$151.0252-Week Low$44.42

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$91.99
    SMA 20$91.67
    SMA 50$94.26
    SMA 200$106.04
    EMA 10$91.26
    EMA 20$91.48
    EMA 50$94.88
    EMA 200$94.44

    MACD

    Line: -0.58Signal: -0.67Hist: 0.09

    ADX

    ADX: 14.4+DI: 15.5-DI: 22.5

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down4.0
    PSAR$85.65

    Bollinger Bands

    Upper Band$96.01
    Lower Band$87.33
    %B Position947%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    45.6

    Momentum Oscillators

    Stoch %K54.9
    Stoch %D68.5
    Williams %R-54.1
    ROC (10d)-3.7%
    Momentum-3.38
    CCI (20d)-148.9
    MFI (14d)58.0

    Volatility Measures

    ATR (14d)$4.65(5.2%)
    StdDev (20d)2.17
    Hist Vol53.0%(High)

    Volume Flow

    VWAP$88.63
    OBV51.9M
    AD Line-15.0M
    CMF (20d)-0.096

    Volume Metrics

    Avg Vol (20d)755.4K
    Vol Ratio1.0x
    VWMA (20d)$91.40

    Pivot Points

    R3$95.45
    R2$93.96
    R1$91.20
    Pivot Point$89.71
    S1$86.95
    S2$85.46
    S3$82.70

    Advanced Oscillators

    TSI-3.03
    Ultimate Osc45.6
    KST-13.76

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$154,000$0$0$121,344$0$0$0$229,648$0
    Cost of RevenueN/A$47,000N/A$41,000$40,000$37,000$35,254$34,021$31,115$29,557$27,948$33,555
    Gross ProfitN/A$-47,000N/A$-41,000$-40,000$-37,000$-35,254$-34,021$-31,115$-29,557$-27,948$-33,555
    Operating Expenses$66.12M$50.46M$49.20M$42.85M$44.01M$36.13M$36.39M$30.06M$24.28M$22.49M$19.70M$18.90M
    R&D$31.08M$33.06M$37.63M$34.91M$40.22M$32.23M$33.47M$27.59M$22.50M$20.65M$18.08M$17.49M
    SG&A$35.04M$17.44M$11.57M$7.93M$3.79M$3.91M$2.96M$2.47M$1.79M$1.85M$1.65M$1.41M
    Operating Income$-66,118,000$-50,507,000$-49,201,000$-42,849,000$-44,009,000$-36,133,000$-36,430,131$-30,059,899$-24,284,000$-22,493,000$-19,729,272$-18,898,037
    Interest Income$0$3.75M$4.39M$3.64M$1.95M$2.32M$3.05M$3.61M$2.82M$2.28M$2.28M$1.87M
    Interest Expense$5.42M$6.08M$6.17M$17.37M$3.20M$3.18M$3.28M$3.34M$2.26M$1.40M$1.40M$1.37M
    Income Before Tax$-78,864,000$-52,841,000$-50,973,000$-43,804,000$-45,268,000$-36,997,000$-36,653,041$-29,791,789$-23,722,000$-21,612,000$-18,848,472$-18,404,540
    Income Tax Expense$0$0$0$0$0$0$-3$0$-5$3$2$1.91M
    Net Income$-78,864,000$-52,841,000$-50,973,000$-43,804,000$-45,268,000$-36,997,000$-36,653,041$-29,791,789$-23,722,000$-21,612,000$-18,848,472$-18,404,540
    EBITDA$-54,641,000$-46,709,000$-44,758,000$-39,168,000$-42,024,000$-33,777,000$-33,342,626$-26,414,107$-21,431,000$-20,181,000$-17,423,277$-16,998,853
    EBITN/A$-46,756,000$-44,807,000$-39,209,000$-42,064,000$-33,814,000$-33,377,880$-26,447,800$-21,462,000$-20,211,000$-17,451,225$-17,032,408
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CELC

    News

    How Investors May Respond To Celcuity (CELC) Deepening Losses As Gedatolisib Commercial Plans Advance

    Celcuity Inc. reported significant net losses in Q2 2026, driven by increased spending for the clinical development and potential commercialization of gedatolisib, particularly REVTORPYK. While the FDA approval of REVTORPYK is a positive catalyst, the widening losses highlight a critical risk: whether future revenue can offset the growing cash burn. The article suggests investors need to assess if REVTORPYK's launch and future trial results will outpace the company's financial commitments.

    Simply Wall Street•8/24/26•
    Neutral

    E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC

    E Fund Management Co. Ltd. has acquired 45,895 shares of Celcuity, Inc. (NASDAQ:CELC), valued at approximately $4.8 million, representing a 0.09% stake in the company. Institutional investors collectively own 63.33% of Celcuity, with several firms adjusting their positions. Despite a recent earnings miss and a stock price below its 52-week high, analysts maintain a "Moderate Buy" consensus rating with an average price target of $154.55.

    MarketBeat•8/20/26•
    Neutral

    Celcuity (CELC) insider logs stock transactions with SEC

    Celcuity Inc.'s CEO, Brian F. Sullivan, reported recent stock transactions to the SEC via a Form 4 filing. The filing indicates that Sullivan acquired 80,000 shares of common stock and 120,000 performance stock units, with details on vesting schedules and beneficial ownership. The report provides a neutral impact and sentiment analysis from Rhea-AI.

    Stock Titan•8/19/26•
    Neutral

    Celcuity (NASDAQ: CELC) insider updates stock holdings

    Celcuity Inc. Chief Science Officer, Lance G. Laing, reported insider transactions via a Form 4 filing, indicating a net purchase of 20,000 shares. These transactions involved the grant of 20,000 common stock shares and 10,000 performance stock units. The common stock vests over four years, while performance units vest upon achieving specific share price thresholds.

    Stock Titan•8/18/26•
    Neutral

    Celcuity (NasdaqCM:CELC) Stock Forecast & Analyst Predictions

    Celcuity (CELC) is forecast to achieve significant earnings and revenue growth, with EPS expected to increase by 68.1% annually. Recent updates include FDA approval for REVTORPYK for breast cancer, targeting a late Q3 2026 commercial launch, and revised breakeven date forecasts. The company faces risks such as negative shareholder equity and past share dilution but shows potential with its lead therapeutic candidate, gedatolisib, in ongoing clinical trials.

    Simply Wall Street•8/18/26•
    Somewhat-Bullish

    Frequently Asked Questions About CELC

    Does CELC pay dividends?
    Celcuity LLC (CELC) does not currently pay a regular dividend.
    What is CELC's market cap?
    Celcuity LLC (CELC) has a market capitalization of $4.33B with a current stock price of $89.06.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In